
Thisvialcontainsa16residueoligopeptidederivedfromthecarboxyterminalregionofhumantopoisomeraseIIa. Thepurityofthepeptidewasgreaterthan95%asdeterminedbyHPLCandmassspectralanalysis. Approximately10mgofpurifiedpeptidewerecoupled(throughaterminalcysteinethiol)toKLHwithaheterobifunctionalcross-linkingagentMBSataratioof1partpeptideto1partKLH. Thepeptidewasusedtoimmunizerabbitsforantibodyproduction.Theresultingantibodyreactsstronglyandspecificallywiththe170kDaHumanTopoIIprotein. Thispeptideisusedasacontrolreagentinimmunofluorescence;iteffectivelyneutralizestheantibodytotopoII.
VialContents:
50ugofC-terminalpeptide(16-mer)inalyophilzedform.
MaterialSafetyData:
THISPRODUCTISNOTLICENSEDORAPPROVEDFORADMINISTRATIONTOHUMANSORTOANIMALSOTHERTHANEXPERIMENTALANIMALS.